Efsoln, Eli Lilly's (LLY.US) weekly insulin, achieved positive results in two Phase 3 clinical trials
Lilly (LLY.US) announced on Thursday that its insulin weekly formulation, efsitora, met the primary endpoint in two Phase 3 clinical trials, QWINT-1 and QWINT-3, indicating a more convenient treatment option for adult patients with type 2 diabetes.
QWINT-1 trial lasted for 52 weeks and included adult patients with type 2 diabetes who were initiating basal insulin. Clinical data showed that at week 52, HbA1c was reduced by 1.31% in the efsitora group and 1.27% in the glargine group, demonstrating non-inferiority. The trial met its primary endpoint.
QWINT-3 trial lasted for 78 weeks and included adult patients with type 2 diabetes currently receiving basal insulin. Clinical data showed that at week 26, HbA1c was reduced by 0.86% in the efsitora group and 0.75% in the degludec group, demonstrating non-inferiority. The trial also met its primary endpoint.
Lilly said that in both trials, the overall safety and tolerability of efsitora was consistent with basal insulin. The company plans to share detailed results in future medical meetings and submit them for publication in peer-reviewed journals.
Jeff Emmick, senior vice president of product development at Lilly, said, "Weekly, convenient, fixed-dose efsitora makes it easier for people with diabetes to start and manage insulin therapy while minimizing the impact on daily life."
It is known that daily insulin injections have been proven effective, but for many patients, frequent injections are a burden. Lilly developed the weekly insulin efsitora to improve the quality of life by reducing the injection frequency.
It is worth noting that in May this year, Lilly announced positive data from two Phase 3 clinical trials, QWINT-2 and QWINT-4, showing that efsitora was non-inferior to the most commonly used daily basal insulin in terms of HbA1c reduction.